Selective HDAC3 Inhibitor Combinations for MHC II Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments, particularly for immune-suppressive cancers, are ineffective due to limited immune system engagement, necessitating more effective combination therapies that enhance immune response.
Innovation Solution
Combining selective histone deacetylase 3 (HDAC3) inhibitors with immune checkpoint inhibitors to increase major histocompatibility complex (MHC) class II expression, thereby enhancing the effectiveness of immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective HDAC3 inhibitors are used to increase MHC class II expression, then immune response effectiveness is improved, but treatment complexity increases due to combination therapy requirements
Solution Approach 1:
The patent combines selective HDAC3 inhibitors with immune checkpoint inhibitors into a unified treatment protocol. The HDAC3 inhibitor increases MHC class II expression on antigen-presenting cells, while the immune checkpoint inhibitor enhances T-cell activation. By merging these two mechanisms, the treatment achieves synergistic effects that overcome immune suppression in cancer, resolving the contradiction between improved immune response effectiveness and treatment complexity through coordinated action of multiple agents.
2Productivity
If combination therapy with HDAC3 inhibitors and immune checkpoint inhibitors is used, then cancer treatment efficacy is improved, but cost and administration burden increase
Solution Approach 1:
The patent employs preliminary action by administering the HDAC3 inhibitor before the immune checkpoint inhibitor in a sequential treatment protocol. The HDAC3 inhibitor is given first to pre-condition the immune system by upregulating MHC class II expression on antigen-presenting cells, creating an optimal state for subsequent immune checkpoint inhibitor administration. This preliminary preparation enhances the overall efficacy of the combination therapy while structuring the administration in a logical sequence that may reduce administrative burden compared to simultaneous or reversed sequencing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of HDAC3 inhibitors and immune checkpoint inhibitors increases MHC class II antigen presentation, leading to improved cancer treatment efficacy by bolstering the immune response against cancer cells.
Implementation Method 1
selective histone deacetylase 3 (HDAC3) inhibitors were shown to be effective at increasing major histocompatibility complex (MHC) class II expression levels
Implementation Method 2
the selective HDAC3 inhibitors may increase MHC II antigen presentation, and the immune checkpoint inhibitor effectiveness may depend on the level of MHC II antigen presentation
Data Source
AI summary
Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histone deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).